Helixmith Co., Ltd.

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Nutraceuticals

Other Names/Subsidiaries

  • Cartexell
  • Genebiotech Co., Ltd
  • Neuromyon
  • ViroMed Co., Ltd.
  • VM BioPharma
  • Helixir
See more in Biomedtracker

Latest on Helixmith Co., Ltd.

Scrip

Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks

 
• By Jung Won Shin

The hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with prog

Scrip

The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?

 
• By Jung Won Shin

While global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor

Scrip

Helixmith’s Plasmid DNA Therapeutic Moves Forward With New Formulation

 
• By Jung Won Shin

Helixmith Co., Ltd. is set to use a new formulation of Engensis (VM202) for an upcoming Phase III trial for diabetic peripheral neuropathy (DPN), a move that may bring the company closer to commercia

Pink Sheet

Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?

 
• By Cathy Kelly

Upcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populat